1. State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China 2. Department of Otolaryngology, South Campus, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
Colorectal cancer (CRC) is a common malignant tumor in the digestive tract, and 30%–85% of CRCs express epidermal growth factor receptors (EGFRs). Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC have been demonstrated to cause an S492R mutation in EGFR. However, little is known about the biological function of S492R EGFR. Therefore, we attempted to elucidate its biological function in CRC cells and explore new treatment strategies for this mutant form. Our study indicated that EGFR and S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibody CH12, which specifically recognizes an EGFR tumor-specific epitope, can bind efficiently to S492R EGFR. Furthermore, mAb CH12 showed significantly stronger growth suppression activities and induced a more potent antibody-dependent cellular cytotoxicity effect on CRC cells bearing S492R EGFR than mAb C225. mAb CH12 obviously suppressed the growth of CRC xenografts with S492R EGFR mutations in vivo. Thus, mAb CH12 may be a promising therapeutic agent in treating patients with CRC bearing an S492R EGFR mutation.
JCEncarnação, ASPires, RAAmaral, TJGonçalves, MLaranjo, JECasalta-Lopes, ACGonçalves, ABSarmento-Ribeiro, AMAbrantes, MFBotelho. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. J Nutr Biochem 2018; 56: 183–192 https://doi.org/10.1016/j.jnutbio.2018.02.018
pmid: 29587241
2
GGoel. Evolution of regorafenib from bench to bedside in colorectal cancer: is it an attractive option or merely a “me too” drug? Cancer Manag Res 2018; 10: 425–437 https://doi.org/10.2147/CMAR.S88825
pmid: 29563833
3
JHStrickler, HI Hurwitz. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014; 16(1): 363 https://doi.org/10.1007/s11912-013-0363-z
pmid: 24293074
4
AKalyan, S Kircher, HShah, MMulcahy, ABenson. Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol 2018; 9(1): 160–169 https://doi.org/10.21037/jgo.2018.01.17
pmid: 29564182
5
MHDietvorst, FA Eskens. Current and novel treatment options for metastatic colorectal cancer: emphasis on aflibercept. Biol Ther 2013; 3(1): 25–33 https://doi.org/10.1007/s13554-013-0009-6
pmid: 24392302
6
ESanz-Garcia, J Grasselli, GArgiles, MEElez, JTabernero. Current and advancing treatments for metastatic colorectal cancer. Expert Opin Biol Ther 2016; 16(1): 93–110 https://doi.org/10.1517/14712598.2016.1108405
pmid: 26549053
7
SYLee, SC Oh. Advances of targeted therapy in treatment of unresectable metastatic colorectal cancer. BioMed Res Int 2016; 2016: 7590245 https://doi.org/10.1155/2016/7590245
pmid: 27127793
8
CTomida, K Aibara, NYamagishi, CYano, H Nagano, TAbe, AOhno, K Hirasaka, TNikawa, STeshima-Kondo. The malignant progression effects of regorafenib in human colon cancer cells. J Med Invest 2015; 62(3-4): 195–198 https://doi.org/10.2152/jmi.62.195
pmid: 26399347
9
LLiang, L Wang, PZhu, YXia, Y Qiao, JWu, WZhuang, JFei, Y Wen, XJiang. A pilot study of apatinib as third-line treatment in patients with heavily treated metastatic colorectal cancer. Clin Colorectal Cancer 2018; 17(3): e443–e449 https://doi.org/10.1016/j.clcc.2018.02.011
pmid: 29576426
10
CTomida, H Nagano, NYamagishi, TUchida, AOhno, K Hirasaka, TNikawa, STeshima-Kondo. Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor. J Med Invest 2017; 64 (3.4): 262–265 https://doi.org/DOI: 10.2152/jmi.64.262
11
TYamaoka, M Ohba, TOhmori. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms. Int J Mol Sci 2017; 18(11): E2420 https://doi.org/10.3390/ijms18112420
pmid: 29140271
12
PSavage, A Blanchet-Cohen, TRevil, DBadescu, SMISaleh, YCWang, DZuo, L Liu, NRBertos, VMunoz-Ramos, MBasik, KPetrecca, JAsselah, SMeterissian, MCGuiot, AOmeroglu, CLKleinman, MPark, J Ragoussis. A targetable EGFR-dependent tumor-initiating program in breast cancer. Cell Reports 2017; 21(5): 1140–1149 https://doi.org/10.1016/j.celrep.2017.10.015
pmid: 29091754
13
PZhou, J Hu, XWang, JWang, Y Zhang, CWang. Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung cancer cells via the extracellular signal-regulated kinase/microRNA 200a signaling pathway. Oncol Lett 2018; 15(4): 5201–5207 https://doi.org/10.3892/ol.2018.7961
pmid: 29552158
14
JLi, R Liang, CSong, YXiang, YLiu. Prognostic significance of epidermal growth factor receptor expression in glioma patients. OncoTargets Ther 2018; 11: 731–742 https://doi.org/10.2147/OTT.S155160
pmid: 29445288
MDel Prete, R Giampieri, LFaloppi, MBianconi, ABittoni, KAndrikou, SCascinu. Panitumumab for the treatment of metastatic colorectal cancer: a review. Immunotherapy 2015; 7(7): 721–738 https://doi.org/10.2217/imt.15.46
pmid: 26250414
18
CMontagut, A Dalmases, BBellosillo, MCrespo, SPairet, MIglesias, MSalido, MGallen, SMarsters, SPTsai, AMinoche, SSeshagiri, SSerrano, HHimmelbauer, JBellmunt, ARovira, JSettleman, FBosch, JAlbanell. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18(2): 221–223 https://doi.org/10.1038/nm.2609
pmid: 22270724
19
CEsposito, AM Rachiglio, MLLa Porta, ASacco, CRoma, A Iannaccone, FTatangelo, LForgione, RPasquale, ABarbaro, GBotti, FCiardiello, NNormanno. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biol Ther 2013; 14(12): 1143–1146 https://doi.org/10.4161/cbt.26340
pmid: 24025416
20
DTougeron, U Cortes, AFerru, CVillalva, CSilvain, JMTourani, PLevillain, LKarayan-Tapon. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol 2013; 72(2): 397–403 https://doi.org/10.1007/s00280-013-2211-0
pmid: 23765179
21
KNewhall, T Price, MPeeters, TWKim, J Li, SCascinu, PRuff, AS Suresh, AThomas, STjulandin, SOgbagabriel, MBoedigheimer, SSexson, KZhang, SMurugappan, RSidhu. Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from metastatic colorectal cancer patients treated with panitumumab or cetuximab monotherapy. Ann Oncol 2014; 25 (suppl_2): ii109 https://doi.org/10.1093/annonc/mdu193.11
22
HJiang, H Wang, ZTan, SHu, H Wang, BShi, LYang, P Li, JGu, HWang, Z Li. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem 2011; 286(7): 5913–5920 https://doi.org/10.1074/jbc.M110.192252
pmid: 21163950
23
HWang, B Shi, QZhang, HJiang, SHu, J Kong, MYao, SYang, Z Li. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation. FASEB J 2012; 26(1): 73–80 https://doi.org/10.1096/fj.11-191064
pmid: 21917986
24
RBLuwor, TG Johns, CMurone, HJHuang, WKCavenee, GRitter, LJOld, AW Burgess, AMScott. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001; 61(14): 5355–5361
pmid: 11454674
25
HJiang, Q Dong, XLuo, BShi, H Wang, HGao, JKong, J Zhang, ZLi. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Lett 2014; 342(1): 113–120 https://doi.org/10.1016/j.canlet.2013.08.038
pmid: 24007863
26
MZhou, H Wang, KZhou, XLuo, X Pan, BShi, HJiang, JZhang, KLi, HM Wang, HGao, SLu, M Yao, YMao, HYWang, SYang, J Gu, CLi, ZLi. A novel EGFR isoform confers increased invasiveness to cancer cells. Cancer Res 2013; 73(23): 7056–7067 https://doi.org/10.1158/0008-5472.CAN-13-0194
pmid: 24240702
27
HWang, H Jiang, MZhou, ZXu, S Liu, BShi, XYao, M Yao, JGu, ZLi. Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma. Cancer Lett 2009; 279(1): 30–38 https://doi.org/10.1016/j.canlet.2009.01.019
pmid: 19217205
28
DBalin-Gauthier, JP Delord, PRochaix, VMallard, FThomas, IHennebelle, RBugat, PCanal, CAllal. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 2006; 57(6): 709–718 https://doi.org/10.1007/s00280-005-0123-3
pmid: 16320055
29
YYang, H Jiang, HGao, JKong, P Zhang, SHu, BShi, P Zhang, MYao, ZLi. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Neoplasia 2012; 14(6): 509–518 https://doi.org/10.1593/neo.12328
pmid: 22787432
30
KLiu, H Gao, QWang, LWang, B Zhang, ZHan, XChen, M Han, MGao. Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer. Cancer Sci 2018; 109(5): 1369–1381 https://doi.org/10.1111/cas.13575
pmid: 29575334
31
CBaratelli, C Zichi, MDi Maio, MPBrizzi, CSonetto, GVScagliotti, MTampellini. A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. Crit Rev Oncol Hematol 2018; 122: 21–29 https://doi.org/10.1016/j.critrevonc.2017.12.010
pmid: 29458787
32
FMde Man, AKL Goey, RHNvan Schaik, RHJMathijssen, SBins. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 2018; 57(10):1229–1254 https://doi.org/10.1007/s40262-018-0644-7
33
KFujita, Y Kubota, HIshida, YSasaki. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015; 21(43): 12234–12248 https://doi.org/10.3748/wjg.v21.i43.12234
pmid: 26604633
34
CLTeng, CY Wang, YHChen, CHLin, WL Hwang. Optimal sequence of irinotecan and oxaliplatin-based regimens in metastatic colorectal cancer: a population-based observational study. PLoS One 2015; 10(8): e0135673 https://doi.org/10.1371/journal.pone.0135673
pmid: 26273837
35
CMontagut, J Albanell. Mechanisms of acquired resistance to anti-EGF receptor treatment in colorectal cancer. Colorectal Cancer 2012; 1(6): 491–502 https://doi.org/10.2217/crc.12.62
36
HKGan, AW Burgess, AHClayton, AMScott. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 2012; 72(12): 2924–2930 https://doi.org/10.1158/0008-5472.CAN-11-3898
pmid: 22659454
37
JERogers. Patient considerations in metastatic colorectal cancer — role of panitumumab. OncoTargets Ther 2017; 10: 2033–2044 https://doi.org/10.2147/OTT.S115430
pmid: 28435294
38
MJhawer, S Goel, AJWilson, CMontagna, YHLing, DSByun, SNasser, DArango, JShin, L Klampfer, LHAugenlicht, RPerez-Soler, JMMariadason. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68(6): 1953–1961 https://doi.org/10.1158/0008-5472.CAN-07-5659
pmid: 18339877
39
WZhang, M Gordon, OAPress, KRhodes, DVallböhmer, DYYang, DPark, W Fazzone, ASchultheis, AESherrod, SIqbal, SGroshen, HJLenz. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with cetuximab. Pharmacogenet Genomics 2006; 16(7): 475–483 https://doi.org/10.1097/01.fpc.0000220562.67595.a5
pmid: 16788380
40
SKong, CI Amos, RLuthra, PMLynch, BLevin, MLFrazier. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000; 60(2): 249–252
pmid: 10667569
41
BCKoehler, AL Scherr, SLorenz, TUrbanik, NKautz, CElssner, SWelte, JLBermejo, DJäger, HSchulze-Bergkamen. Beyond cell death — antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLoS One 2013; 8(10): e76446 https://doi.org/10.1371/journal.pone.0076446
pmid: 24098503
42
QRQi, ZM Yang. Regulation and function of signal transducer and activator of transcription 3. World J Biol Chem 2014; 5(2): 231–239
pmid: 24921012